Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2019-08-14 Interim / Quarterly Rep…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Genmab Announces Financial Results for the First Half of 2019 and Updates 2019 Financial Guidance
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report for the First Half of 2019' and contains comprehensive financial statements, including consolidated key figures, income statements, balance sheets, cash flow statements, and management's discussion of financial performance and outlook. It is clearly a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2019
2019-08-14 English
Report Publication Announcement 2019
Report Publication Announcement Classification · 95% confidence The document is a press release announcing the financial results for the first half of 2019. While it contains summary financial data, highlights, and guidance, it explicitly directs the reader to download the 'full Interim Report' via an attachment link at the end of the text. According to the 'Menu vs Meal' rule, a document that announces the publication of a report and provides a link to it is classified as a Report Publication Announcement (RPA). H1 2019
2019-08-14 English
6-K
Foreign Filer Report
2019-07-23 English
Genmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement regarding the closing of an over-allotment option in an IPO and the subsequent registration of a capital increase (issuance of new shares). This directly relates to changes in the company's capital structure and share issuance. According to the provided definitions, 'Share Issue/Capital Change' (SHA) is the most accurate category for announcements regarding new share issues and capital changes.
2019-07-23 English
Genmab Announces the Closing of Over-Allotment Option in Initial Public Offering of American Depositary Shares (ADSs) in the United States and Registration of Capital Increase
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement regarding the closing of an over-allotment option in an Initial Public Offering (IPO) and the subsequent registration of a capital increase. It details the issuance of new shares, the impact on total share capital, and the listing status. This falls under the category of share issuance and capital changes, which is specifically defined as 'Share Issue/Capital Change' (SHA).
2019-07-23 English
6-K
Foreign Filer Report
2019-07-22 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.